Clinical trial
Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
NCT00325429 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00325429 |
|---|---|
| Title | Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes |
| Official title | A Multicenter, Open, Long Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Vildagliptin |
| Enrollment | 150 |
| Start date | Apr 1, 2006 |
| First posted | May 12, 2006 |
| Last update posted | Jan 7, 2009 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: